Amplia (ASX:ATX) has today announced it is undertaking a fully underwritten Entitlement Offer to raise $4.27m. Under the Entitlement Offer, eligible shareholders will be able to subscribe for two (2) New Shares for every five (5) shares held.
Funds from this capital raise will be used to support Amplia’s ongoing Phase 2a ACCENT trial and undertake the Interim Analysis, produce additional narmafotinib and manufacture a further batch of 25,000 capsules, and support a pilot Investigator Initiated Trial in ovarian cancer.
Click here to read today’s ASX release.
Click here to view the Investor Presentation
